Clinical Trial Update: A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating sacituzumab govitecan in platinum-resistant ovarian cancer; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Yale University | Conditions: Ovarian Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING